Navigation Links
Logical Therapeutics Secures $16.9M Series C Financing Round
Date:5/26/2010

Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients

WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing.  The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

Logical Therapeutics is developing a family of new chemical entities using its patented Bio-activated Technology.TM The proprietary platform, which modifies the chemical structure of NSAIDs (non-steroidal anti-inflammatory drugs), is being developed to significantly reduce the gastrointestinal (GI) side effects often associated with NSAIDs.  The Company's lead compound, LT-NS001 (naproxen etemesil), is currently being studied in a Phase 2b/3 study comparing the cumulative rate of gastric ulcers vs. Naprosyn® in osteoarthritis patients after 12 weeks of treatment.  Completion of the study is expected in late 2010.

The Series C financing round is expected to provide sufficient capital to advance the Company's development program through further clinical and non-clinical activities necessary for registration. The Company intends to seek a business partner prior to commercialization.  

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biopharmaceutical company focused on the development of bio-activated prodrugs to treat inflammatory conditions such as osteoarthritis and rheumatoid arthritis.  The Company's Bio-activated TechnologyTM has created a portfolio of molecules including LT-NS001, a naproxen prodrug and several additional bio-activated NSAID prodrug candidates, which are covered by issued and pending U.S. and international patents.  Each program addresses unmet medical needs in multi-billion dollar markets.  For more information about Logical Therapeutics, visit the Company's website at www.logicaltx.com.

LT-NS001 is an investigational drug product candidate undergoing clinical evaluation and has not been approved by the U.S. Food and Drug Administration.

Bio-activated TechnologyTM is a trademark of Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
4. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
5. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
6. Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
7. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
8. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
9. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
10. Reportlinker Adds Audiological Devices - Global Market Trends
11. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Kingdom and  BOSTON , March 28, 2017 ... Linguamatics today announced a partnership with premium ... agreement allows pharmaceutical companies to extract key insights ... text mining technology. The Linguamatics ... the top 20 global pharmaceutical companies. The Linguamatics-Dow ...
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... 2017 Elysium Health joins major ... Cambridge academic scientists ... The Milner Therapeutics Institute today announces Elysium Health as a ... significant investment for collaborative projects with academic researchers in ... is the first major research investment outside the U.S. for ...
Breaking Medicine Technology:
(Date:3/28/2017)... Washington and CARTERSVILLE, Georgia (PRWEB) , ... March ... ... another senior analyst to its award-winning team. Ruel Williamson brings his extensive knowledge ... which has been a leader in the real estate valuation industry for more ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied ... as new board chair for Orange County health care system CalOptima Friday. CalOptima ... soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of this ...
(Date:3/28/2017)... WI (PRWEB) , ... March 28, 2017 , ... ... self-funded health plans work, the Self-Funding Success website has recently developed and published ... Self-Funded Health Plans ” was created based on common inquiries the site’s team ...
Breaking Medicine News(10 mins):